CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Ca...( VIENNA Va. March 3 /- CEL-SCI COR...),Health

VIENNA, Va., March 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) provided details today at its 2008 Annual Meeting of Shareholders on groundbreaking activities currently underway at its manufacturing facility near Baltimore, Maryland. The facility will be used to manufacture Multikine(R), the Company's lead compound, for a pivotal Phase III clinical trial as first-line therapy of previously untreated head and neck cancer patients. The facility, which is being built by the design builder BE&K (http://www.bek.com/index.asp), is expected to be completed during the third quarter of 2008, with manufacturing and patient enrollment to begin soon thereafter.

"I am excited to announce to our shareholders the excellent progress we have made in constructing our manufacturing facility in the short period of time since we have broken ground," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We believe the facility will provide us with tight control over the manufacturing process, eliminating a key risk of the pivotal trial. Multikine represents a completely novel medicine with blockbuster potential to treat a large unmet medical need and we are eager to begin this open label trial."

Mr. Kersten continued, "We are starting to receive more recognition for our work. The February 2008 issue of MedAdNews, a highly respected and authoritative publication serving the pharmaceutical industry, ran its 8th annual report on FUTURE BLOCKBUSTERS stating that 'These medicines are expected to eventually garner FDA approval and break the annual billion-dollar sales barrier'. Our Multikine was one of the 10 medicines named."

The article can be accessed on CEL-SCI's websit
'/>"/>